News
-
-
PRESS RELEASE
Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World
Aspire Biopharma unveils sublingual BUZZ BOMB™ pre-workout supplement with rapid 50mg caffeine delivery, targeting fitness conventions in Salt Lake City and Anaheim -
-
-
PRESS RELEASE
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement
Aspire Biopharma announces positive consumer feedback for BUZZ BOMB™, a sublingual pre-workout supplement with fast-acting caffeine delivery technology for athletes and fitness enthusiasts. Plans for product launch at FITCON and Fit Expo conventions in August -
-
-
PRESS RELEASE
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
Aspire Biopharma completes Phase 1 trial enrollment for fast-acting high-dose aspirin formulation, expecting topline results in mid Q3 2025 -
-
